Details
Stereochemistry | ACHIRAL |
Molecular Formula | C29H35F3N2O3 |
Molecular Weight | 516.595 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=C(CN2CC(C2)C(O)=O)C=CC(=C1)C(\C)=N\OCC3=CC(=C(C=C3)C4CCCCC4)C(F)(F)F
InChI
InChIKey=KIHYPELVXPAIDH-HNSNBQBZSA-N
InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+
Siponimod (BAF312) is a dual agonist at the sphingosine-1 phosphate receptors, S1PR1 and S1PR5. The S1P receptor is commonly found on the surface of specific cells residing in the central nervous system (CNS), that are responsible for causing CNS damage that drives loss of function in secondary progressive multiple sclerosis (SPMS). Siponimod (BAF312) enters the brain and by binding to these specific receptors, may prevent the activation of these harmful cells, helping to reduce the loss of physical and cognitive function associated with SPMS.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22646698
Curator's Comment: # Novartis Pharma AG
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4333 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22646698 |
0.39 nM [EC50] | ||
Target ID: CHEMBL2274 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22646698 |
0.98 nM [EC50] | ||
Target ID: CHEMBL3230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22646698 |
750.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | SIPONIMOD Approved UseUnknown |
|||
Palliative | SIPONIMOD Approved UseUnknown |
|||
Palliative | SIPONIMOD Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30.4 ng/mL |
2 mg 1 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SIPONIMOD plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
558 ng × h/mL |
2 mg 1 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SIPONIMOD plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30 h |
2 mg 1 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SIPONIMOD plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1 mg single, intravenous Dose: 1 mg Route: intravenous Route: single Dose: 1 mg Sources: |
healthy, 18-50 years |
Other AEs: Feeling hot, Dizziness... Other AEs: Feeling hot (5.9%) Sources: Dizziness (5.9%) Headache (5.9%) Presyncope (5.9%) Blurred vision (5.9%) Dry lips (5.9%) Nasopharyngitis (5.9%) Vaginal discharge (5.9%) |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Disc. AE: Headache, Transaminases increased... AEs leading to discontinuation/dose reduction: Headache (0.1%) Sources: Transaminases increased (0.9%) |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Disc. AE: Hypertension... AEs leading to discontinuation/dose reduction: Hypertension (10%) Sources: |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Disc. AE: Macular edema, ALT increased... AEs leading to discontinuation/dose reduction: Macular edema (1%) Sources: ALT increased (0.5%) Bradycardia (0.3%) GGT increased (0.3%) AST increased (0.3%) Depression (0.3%) Dizziness (0.3%) Fatigue (0.3%) Pulmonary function test decreased (0.3%) Angina pectoris (0.2%) Edema peripheral (0.2%) Seminoma (0.2%) Uveitis (0.2%) Lymphopenia (0.1%) Urinary tract infection (0.1%) |
20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
Other AEs: Headache, Dizziness... Other AEs: Headache (20.8%) Sources: Dizziness (5.7%) Nausea (4.2%) |
75 mg single, oral Highest studied dose Dose: 75 mg Route: oral Route: single Dose: 75 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
Other AEs: Headache, Dizziness... Other AEs: Headache (32%) Sources: Dizziness (12.1%) Nausea (5.5%) |
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Disc. AE: Macular edema, ALT increased... AEs leading to discontinuation/dose reduction: Macular edema (2%) Sources: ALT increased (2%) ALT increased (2%) AST increased (2%) Dizziness (4%) Edema peripheral (2%) Headache (2%) Lymphopenia (4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Blurred vision | 5.9% | 1 mg single, intravenous Dose: 1 mg Route: intravenous Route: single Dose: 1 mg Sources: |
healthy, 18-50 years |
Dizziness | 5.9% | 1 mg single, intravenous Dose: 1 mg Route: intravenous Route: single Dose: 1 mg Sources: |
healthy, 18-50 years |
Dry lips | 5.9% | 1 mg single, intravenous Dose: 1 mg Route: intravenous Route: single Dose: 1 mg Sources: |
healthy, 18-50 years |
Feeling hot | 5.9% | 1 mg single, intravenous Dose: 1 mg Route: intravenous Route: single Dose: 1 mg Sources: |
healthy, 18-50 years |
Headache | 5.9% | 1 mg single, intravenous Dose: 1 mg Route: intravenous Route: single Dose: 1 mg Sources: |
healthy, 18-50 years |
Nasopharyngitis | 5.9% | 1 mg single, intravenous Dose: 1 mg Route: intravenous Route: single Dose: 1 mg Sources: |
healthy, 18-50 years |
Presyncope | 5.9% | 1 mg single, intravenous Dose: 1 mg Route: intravenous Route: single Dose: 1 mg Sources: |
healthy, 18-50 years |
Vaginal discharge | 5.9% | 1 mg single, intravenous Dose: 1 mg Route: intravenous Route: single Dose: 1 mg Sources: |
healthy, 18-50 years |
Headache | 0.1% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Transaminases increased | 0.9% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Hypertension | 10% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Lymphopenia | 0.1% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Urinary tract infection | 0.1% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Angina pectoris | 0.2% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Edema peripheral | 0.2% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Seminoma | 0.2% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Uveitis | 0.2% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
AST increased | 0.3% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Bradycardia | 0.3% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Depression | 0.3% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Dizziness | 0.3% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Fatigue | 0.3% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
GGT increased | 0.3% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Pulmonary function test decreased | 0.3% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
ALT increased | 0.5% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Macular edema | 1% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 49.0 years Health Status: unhealthy Age Group: 49.0 years Sex: M+F Sources: |
Headache | 20.8% | 20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
Nausea | 4.2% | 20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
Dizziness | 5.7% | 20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
Dizziness | 12.1% | 75 mg single, oral Highest studied dose Dose: 75 mg Route: oral Route: single Dose: 75 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
Headache | 32% | 75 mg single, oral Highest studied dose Dose: 75 mg Route: oral Route: single Dose: 75 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
Nausea | 5.5% | 75 mg single, oral Highest studied dose Dose: 75 mg Route: oral Route: single Dose: 75 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
ALT increased | 2% Disc. AE |
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
ALT increased | 2% Disc. AE |
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
AST increased | 2% Disc. AE |
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Edema peripheral | 2% Disc. AE |
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Headache | 2% Disc. AE |
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Macular edema | 2% Disc. AE |
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Dizziness | 4% Disc. AE |
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Lymphopenia | 4% Disc. AE |
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000ClinPharmR.pdf#page=11 Page: 11.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000ClinPharmR.pdf#page=11 Page: 11.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000ClinPharmR.pdf#page=11 Page: 11.0 |
no | |||
Page: 16.0 |
yes | yes (co-administration study) Comment: administered with fluconazole (moderate CYP2C9 and CYP3A4 dual inhibitor): increased siponimod’s Cmax by 10% and the AUC 2-fold; administered with rifampin (strong CYP3A4 and moderate CYP2C9 dual inducer) decreased siponimod AUCtau,ss and Cmax,ss by 57% and 45%, respectively. Page: 16.0 |
||
yes | yes (pharmacogenomic study) Comment: administered with fluconazole (moderate CYP2C9 and CYP3A4 dual inhibitor): increased siponimod’s Cmax by 10% and the AUC 2-fold; administered with rifampin (strong CYP3A4 and moderate CYP2C9 dual inducer) decreased siponimod AUCtau,ss and Cmax,ss by 57% and 45%, respectively. Page: 16.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000PharmR.pdf#page=23 Page: 23.0 |
Sample Use Guides
Patients received 2 mg once daily siponimod (following initial dose titration starting at 0.25 mg).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22646698
The selectivity of siponimod (BAF312) for receptor subtypes S1P1 and S1P5, sparing activity on the S1P2, S1P3 and S1P4 receptors, was demonstrated by measuring agonist efficacy in the GTPγ[35S] binding assay. The half-maximal effective concentration (EC50) values were in the sub-nanomolar range for S1P1 (0.39 ± 0.07 nM) and S1P5 (0.98 ± 0.43 nM) receptors, with Emax levels of approximately 100% (full agonist).
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
437614
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
||
|
FDA ORPHAN DRUG |
413413
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
||
|
NCI_THESAURUS |
C308
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/14/1370
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
RR6P8L282I
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
Siponimod
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
9491
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
2121085
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
FG-55
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
Siponimod
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
1230487-00-9
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
100000163287
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
m12146
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
44599207
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
DTXSID40153847
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
SUB177510
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
5326
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
DB12371
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
C152368
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
CHEMBL2336071
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY | |||
|
RR6P8L282I
Created by
admin on Mon Mar 31 20:55:28 GMT 2025 , Edited by admin on Mon Mar 31 20:55:28 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE INACTIVE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)